Vaxcyte (PCVX) Reiterated at Overweight by Cantor Fitzgerald Afters OPUS-1 Top Line

October 19, 2026 7:29 AM

Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $120.00 price target on Vaxcyte (NASDAQ: PCVX).The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found